The board meeting for Avidity Biosciences Inc is scheduled for today, for the purpose of Morgan Stanley 23rd Annual Global Healthcare ConferenceSee details
Avidity Biosciences Inc has a share price target of US$ 67, revenue growth forecast of -19.1%, and profit growth estimate of -77.8% for FY25, based on top 18 analyst calls.